top of page

MitoStem

A universal T-cell quality enhancer designed to increase Tscm across donors, media, and protocols.

Key features:

  • Mitochondrial reprogramming: biases T-cell fate toward long-lived immune memory cells

  • Clinical compatibility: works with xeno-free media, cytokines, and vessels

  • Process-ready: traceable, washable, and analytically detectable for regulatory confidence

MitoStem™ consistently increases Tscm

image.png

% Cells

Control

MitoStem

Less differentiated cells

CCR7+ CD45RA+ (Tscm)

CCR7+ CD45RA- (Tcm)

CCR7- CD45RA- (Tem)

CCR7- CD45RA+ (Temra)

image.png

Phenotypic markers

Figure 1.

Cells activated with TransAct and cultured for 10 days in 24-well G-REX plates in xeno-free medium with 30 IU/mL IL-2, 10 ng/mL IL-7 and 10 ng/mL IL-15

Flacon-MitoGrow-fondtransparent-ombre-V1.png

MitoGrow

Drop-in manufacturing reagent that accelerates CAR-T expansion, shortening production timelines and lowering cost per dose.

Key features:

  • Faster expansion:cuts manufacturing time by up to 20%

  • Clinical compatibility: works universally across cell culture media and manufacturing systems.

  • Process-ready: traceable, washable, and analytically detectable for regulatory confidence

Faster manufacturing at lower cost

Total number of cells (in x10 Millions)

image.png
image.png
image.png
image.png

Control

MitoGrow

Figure 2.

Frozen human T-cells from healthy donors; cultured in G-REX; in Xeno-free media with TransAct T-cell activation reagent and supplements : IL-2, IL-7, IL-15

Flacon-MitoFit-fondtransparent-ombre-V1.png

MitoFit

Drop-in manufacturing reagent that improves CAR-T metabolic fitness, resulting in stronger anti-tumor activity.

Key features:

  • Enhanced in vivo efficacy: peer-reviewed performance in relevant tumor models (Cell Metabolism; Molecular Therapy Oncology)​

  • Best-in-class metabolic modulation: outperforms established metabolic inhibitors ​

  • Process-ready: traceable, washable, and analytically detectable for regulatory confidence

Stronger CAR T killing power

image.png

Survival rate

Days

Untreated mice (0% survival)

Standard CAR T cells

MitoFit CAR T cells

Figure 3.

​

Humanized NSG xenograft model (NALM6)

CD19 CAR T manufactured ± MitoFit.

40% survival

THE MITO RANGE

Plug-and-Play metabolic tools that enhance consistency, durability, and performance of CAR T cells.

bottom of page